

Global Recombinant Influenza Vaccine Market Growth 2026-2032

<https://marketpublishers.com/r/G91F888A87E2EN.html>

Date: September 2026

Pages: 84

Price: US\$ 3,660.00 (Single User License)

ID: G91F888A87E2EN

Abstracts

The global Recombinant Influenza Vaccine market size is predicted to grow from US\$ 131 million in 2025 to US\$ 234 million in 2032; it is expected to grow at a CAGR of 8.8% from 2026 to 2032.

Recombinant technology plays an important role in the preparation of influenza vaccines. It allows scientists to create and express specific influenza virus proteins through genetic engineering to prepare influenza vaccines. This approach typically involves inserting the genetic sequence of the influenza virus into an expression system, enabling it to produce viral antigen proteins, and then using these proteins to prepare a vaccine.

A significant driver in the Influenza Vaccine market is the growing awareness of the importance of vaccination in preventing seasonal and pandemic influenza outbreaks. As healthcare organizations and governments worldwide promote vaccination as a crucial public health measure, there is an increasing demand for influenza vaccines. Additionally, advances in vaccine research and development, including the production of more effective and broader-spectrum vaccines, are driving market growth. One of the key challenges in this market is the need for frequent vaccine updates to match evolving influenza strains. The virus undergoes genetic changes, requiring annual adjustments to vaccine formulations. This presents logistical challenges for manufacturers in terms of timely production and distribution. Vaccine hesitancy and misinformation also pose challenges by impacting vaccination rates and public perception. Lastly, ensuring equitable access to vaccines, especially in low-income and underserved populations, remains a persistent challenge in the fight against influenza.

LP Information, Inc. (LPI) ' newest research report, the "Recombinant Influenza Vaccine

Industry Forecast” looks at past sales and reviews total world Recombinant Influenza Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Recombinant Influenza Vaccine sales for 2026 through 2032. With Recombinant Influenza Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Recombinant Influenza Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Influenza Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Influenza Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Influenza Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Influenza Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Influenza Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Influenza Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Vial

Prefilled

Segmentation by Application:

Public Sector

Private Sector

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Sanofi

Key Questions Addressed in this Report

What is the 10-year outlook for the global Recombinant Influenza Vaccine market?

What factors are driving Recombinant Influenza Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Recombinant Influenza Vaccine market opportunities vary by end market size?

How does Recombinant Influenza Vaccine break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Recombinant Influenza Vaccine Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Recombinant Influenza Vaccine by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Recombinant Influenza Vaccine by Country/Region, 2021, 2025 & 2032
- 2.2 Recombinant Influenza Vaccine Segment by Type
 - 2.2.1 Vial
 - 2.2.2 Prefilled
 - 2.2.3 Recombinant Influenza Vaccine Sales by Type
 - 2.2.3.1 Global Recombinant Influenza Vaccine Sales Market Share by Type (2021-2026)
 - 2.2.3.2 Global Recombinant Influenza Vaccine Revenue and Market Share by Type (2021-2026)
 - 2.2.3.3 Global Recombinant Influenza Vaccine Sale Price by Type (2021-2026)
- 2.3 Recombinant Influenza Vaccine Segment by Application
 - 2.3.1 Public Sector
 - 2.3.2 Private Sector
 - 2.3.3 Recombinant Influenza Vaccine Sales by Application
 - 2.3.3.1 Global Recombinant Influenza Vaccine Sale Market Share by Application (2021-2026)
 - 2.3.3.2 Global Recombinant Influenza Vaccine Revenue and Market Share by Application (2021-2026)
 - 2.3.3.3 Global Recombinant Influenza Vaccine Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

- 3.1 Global Recombinant Influenza Vaccine Breakdown Data by Company
 - 3.1.1 Global Recombinant Influenza Vaccine Annual Sales by Company (2021-2026)
 - 3.1.2 Global Recombinant Influenza Vaccine Sales Market Share by Company (2021-2026)
- 3.2 Global Recombinant Influenza Vaccine Annual Revenue by Company (2021-2026)
 - 3.2.1 Global Recombinant Influenza Vaccine Revenue by Company (2021-2026)
 - 3.2.2 Global Recombinant Influenza Vaccine Revenue Market Share by Company (2021-2026)
- 3.3 Global Recombinant Influenza Vaccine Sale Price by Company
- 3.4 Key Manufacturers Recombinant Influenza Vaccine Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Recombinant Influenza Vaccine Product Location Distribution
 - 3.4.2 Players Recombinant Influenza Vaccine Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR RECOMBINANT INFLUENZA VACCINE BY GEOGRAPHIC REGION

- 4.1 World Historic Recombinant Influenza Vaccine Market Size by Geographic Region (2021-2026)
 - 4.1.1 Global Recombinant Influenza Vaccine Annual Sales by Geographic Region (2021-2026)
 - 4.1.2 Global Recombinant Influenza Vaccine Annual Revenue by Geographic Region (2021-2026)
- 4.2 World Historic Recombinant Influenza Vaccine Market Size by Country/Region (2021-2026)
 - 4.2.1 Global Recombinant Influenza Vaccine Annual Sales by Country/Region (2021-2026)
 - 4.2.2 Global Recombinant Influenza Vaccine Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Recombinant Influenza Vaccine Sales Growth
- 4.4 APAC Recombinant Influenza Vaccine Sales Growth

4.5 Europe Recombinant Influenza Vaccine Sales Growth

4.6 Middle East & Africa Recombinant Influenza Vaccine Sales Growth

5 AMERICAS

5.1 Americas Recombinant Influenza Vaccine Sales by Country

5.1.1 Americas Recombinant Influenza Vaccine Sales by Country (2021-2026)

5.1.2 Americas Recombinant Influenza Vaccine Revenue by Country (2021-2026)

5.2 Americas Recombinant Influenza Vaccine Sales by Type (2021-2026)

5.3 Americas Recombinant Influenza Vaccine Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Recombinant Influenza Vaccine Sales by Region

6.1.1 APAC Recombinant Influenza Vaccine Sales by Region (2021-2026)

6.1.2 APAC Recombinant Influenza Vaccine Revenue by Region (2021-2026)

6.2 APAC Recombinant Influenza Vaccine Sales by Type (2021-2026)

6.3 APAC Recombinant Influenza Vaccine Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Recombinant Influenza Vaccine by Country

7.1.1 Europe Recombinant Influenza Vaccine Sales by Country (2021-2026)

7.1.2 Europe Recombinant Influenza Vaccine Revenue by Country (2021-2026)

7.2 Europe Recombinant Influenza Vaccine Sales by Type (2021-2026)

7.3 Europe Recombinant Influenza Vaccine Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Recombinant Influenza Vaccine by Country

8.1.1 Middle East & Africa Recombinant Influenza Vaccine Sales by Country
(2021-2026)

8.1.2 Middle East & Africa Recombinant Influenza Vaccine Revenue by Country
(2021-2026)

8.2 Middle East & Africa Recombinant Influenza Vaccine Sales by Type (2021-2026)

8.3 Middle East & Africa Recombinant Influenza Vaccine Sales by Application
(2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Recombinant Influenza Vaccine

10.3 Manufacturing Process Analysis of Recombinant Influenza Vaccine

10.4 Industry Chain Structure of Recombinant Influenza Vaccine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Recombinant Influenza Vaccine Distributors

11.3 Recombinant Influenza Vaccine Customer

12 WORLD FORECAST REVIEW FOR RECOMBINANT INFLUENZA VACCINE BY GEOGRAPHIC REGION

12.1 Global Recombinant Influenza Vaccine Market Size Forecast by Region

12.1.1 Global Recombinant Influenza Vaccine Forecast by Region (2027-2032)

12.1.2 Global Recombinant Influenza Vaccine Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Recombinant Influenza Vaccine Forecast by Type (2027-2032)

12.7 Global Recombinant Influenza Vaccine Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Sanofi

13.1.1 Sanofi Company Information

13.1.2 Sanofi Recombinant Influenza Vaccine Product Portfolios and Specifications

13.1.3 Sanofi Recombinant Influenza Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Sanofi Main Business Overview

13.1.5 Sanofi Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Recombinant Influenza Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Recombinant Influenza Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Vial

Table 4. Major Players of Prefilled

Table 5. Global Recombinant Influenza Vaccine Sales by Type (2021-2026) & (K Units)

Table 6. Global Recombinant Influenza Vaccine Sales Market Share by Type (2021-2026)

Table 7. Global Recombinant Influenza Vaccine Revenue by Type (2021-2026) & (\$ million)

Table 8. Global Recombinant Influenza Vaccine Revenue Market Share by Type (2021-2026)

Table 9. Global Recombinant Influenza Vaccine Sale Price by Type (2021-2026) & (US\$/Unit)

Table 10. Global Recombinant Influenza Vaccine Sale by Application (2021-2026) & (K Units)

Table 11. Global Recombinant Influenza Vaccine Sale Market Share by Application (2021-2026)

Table 12. Global Recombinant Influenza Vaccine Revenue by Application (2021-2026) & (\$ million)

Table 13. Global Recombinant Influenza Vaccine Revenue Market Share by Application (2021-2026)

Table 14. Global Recombinant Influenza Vaccine Sale Price by Application (2021-2026) & (US\$/Unit)

Table 15. Global Recombinant Influenza Vaccine Sales by Company (2021-2026) & (K Units)

Table 16. Global Recombinant Influenza Vaccine Sales Market Share by Company (2021-2026)

Table 17. Global Recombinant Influenza Vaccine Revenue by Company (2021-2026) & (\$ millions)

Table 18. Global Recombinant Influenza Vaccine Revenue Market Share by Company (2021-2026)

Table 19. Global Recombinant Influenza Vaccine Sale Price by Company (2021-2026) & (US\$/Unit)

Table 20. Key Manufacturers Recombinant Influenza Vaccine Producing Area Distribution and Sales Area
Table 21. Players Recombinant Influenza Vaccine Products Offered
Table 22. Recombinant Influenza Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Recombinant Influenza Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Recombinant Influenza Vaccine Sales Market Share Geographic Region (2021-2026)
Table 27. Global Recombinant Influenza Vaccine Revenue by Geographic Region (2021-2026) & (\$ millions)
Table 28. Global Recombinant Influenza Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Recombinant Influenza Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Recombinant Influenza Vaccine Sales Market Share by Country/Region (2021-2026)
Table 31. Global Recombinant Influenza Vaccine Revenue by Country/Region (2021-2026) & (\$ millions)
Table 32. Global Recombinant Influenza Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Recombinant Influenza Vaccine Sales by Country (2021-2026) & (K Units)
Table 34. Americas Recombinant Influenza Vaccine Sales Market Share by Country (2021-2026)
Table 35. Americas Recombinant Influenza Vaccine Revenue by Country (2021-2026) & (\$ millions)
Table 36. Americas Recombinant Influenza Vaccine Sales by Type (2021-2026) & (K Units)
Table 37. Americas Recombinant Influenza Vaccine Sales by Application (2021-2026) & (K Units)
Table 38. APAC Recombinant Influenza Vaccine Sales by Region (2021-2026) & (K Units)
Table 39. APAC Recombinant Influenza Vaccine Sales Market Share by Region (2021-2026)
Table 40. APAC Recombinant Influenza Vaccine Revenue by Region (2021-2026) & (\$ millions)

Table 41. APAC Recombinant Influenza Vaccine Sales by Type (2021-2026) & (K Units)
Table 42. APAC Recombinant Influenza Vaccine Sales by Application (2021-2026) & (K Units)
Table 43. Europe Recombinant Influenza Vaccine Sales by Country (2021-2026) & (K Units)
Table 44. Europe Recombinant Influenza Vaccine Revenue by Country (2021-2026) & (\$ millions)
Table 45. Europe Recombinant Influenza Vaccine Sales by Type (2021-2026) & (K Units)
Table 46. Europe Recombinant Influenza Vaccine Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Recombinant Influenza Vaccine Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Recombinant Influenza Vaccine Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Recombinant Influenza Vaccine Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Recombinant Influenza Vaccine Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Recombinant Influenza Vaccine
Table 52. Key Market Challenges & Risks of Recombinant Influenza Vaccine
Table 53. Key Industry Trends of Recombinant Influenza Vaccine
Table 54. Recombinant Influenza Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Recombinant Influenza Vaccine Distributors List
Table 57. Recombinant Influenza Vaccine Customer List
Table 58. Global Recombinant Influenza Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Recombinant Influenza Vaccine Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 60. Americas Recombinant Influenza Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Recombinant Influenza Vaccine Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 62. APAC Recombinant Influenza Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Recombinant Influenza Vaccine Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 64. Europe Recombinant Influenza Vaccine Sales Forecast by Country (2027-2032) & (K Units)

Table 65. Europe Recombinant Influenza Vaccine Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 66. Middle East & Africa Recombinant Influenza Vaccine Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Middle East & Africa Recombinant Influenza Vaccine Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Global Recombinant Influenza Vaccine Sales Forecast by Type (2027-2032) & (K Units)

Table 69. Global Recombinant Influenza Vaccine Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 70. Global Recombinant Influenza Vaccine Sales Forecast by Application (2027-2032) & (K Units)

Table 71. Global Recombinant Influenza Vaccine Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 72. Sanofi Basic Information, Recombinant Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 73. Sanofi Recombinant Influenza Vaccine Product Portfolios and Specifications

Table 74. Sanofi Recombinant Influenza Vaccine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 75. Sanofi Main Business

Table 76. Sanofi Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Recombinant Influenza Vaccine
- Figure 2. Recombinant Influenza Vaccine Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Recombinant Influenza Vaccine Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Recombinant Influenza Vaccine Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Recombinant Influenza Vaccine Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Recombinant Influenza Vaccine Sales Market Share by Country/Region (2025)
- Figure 10. Recombinant Influenza Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Vial
- Figure 12. Product Picture of Prefilled
- Figure 13. Global Recombinant Influenza Vaccine Sales Market Share by Type in 2026
- Figure 14. Global Recombinant Influenza Vaccine Revenue Market Share by Type (2021-2026)
- Figure 15. Recombinant Influenza Vaccine Consumed in Public Sector
- Figure 16. Global Recombinant Influenza Vaccine Market: Public Sector (2021-2026) & (K Units)
- Figure 17. Recombinant Influenza Vaccine Consumed in Private Sector
- Figure 18. Global Recombinant Influenza Vaccine Market: Private Sector (2021-2026) & (K Units)
- Figure 19. Global Recombinant Influenza Vaccine Sale Market Share by Application (2025)
- Figure 20. Global Recombinant Influenza Vaccine Revenue Market Share by Application in 2026
- Figure 21. Recombinant Influenza Vaccine Sales by Company in 2026 (K Units)
- Figure 22. Global Recombinant Influenza Vaccine Sales Market Share by Company in 2026
- Figure 23. Recombinant Influenza Vaccine Revenue by Company in 2026 (\$ millions)
- Figure 24. Global Recombinant Influenza Vaccine Revenue Market Share by Company

in 2026

Figure 25. Global Recombinant Influenza Vaccine Sales Market Share by Geographic Region (2021-2026)

Figure 26. Global Recombinant Influenza Vaccine Revenue Market Share by Geographic Region in 2026

Figure 27. Americas Recombinant Influenza Vaccine Sales 2021-2026 (K Units)

Figure 28. Americas Recombinant Influenza Vaccine Revenue 2021-2026 (\$ millions)

Figure 29. APAC Recombinant Influenza Vaccine Sales 2021-2026 (K Units)

Figure 30. APAC Recombinant Influenza Vaccine Revenue 2021-2026 (\$ millions)

Figure 31. Europe Recombinant Influenza Vaccine Sales 2021-2026 (K Units)

Figure 32. Europe Recombinant Influenza Vaccine Revenue 2021-2026 (\$ millions)

Figure 33. Middle East & Africa Recombinant Influenza Vaccine Sales 2021-2026 (K Units)

Figure 34. Middle East & Africa Recombinant Influenza Vaccine Revenue 2021-2026 (\$ millions)

Figure 35. Americas Recombinant Influenza Vaccine Sales Market Share by Country in 2026

Figure 36. Americas Recombinant Influenza Vaccine Revenue Market Share by Country (2021-2026)

Figure 37. Americas Recombinant Influenza Vaccine Sales Market Share by Type (2021-2026)

Figure 38. Americas Recombinant Influenza Vaccine Sales Market Share by Application (2021-2026)

Figure 39. United States Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 40. Canada Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 41. Mexico Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 42. Brazil Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 43. APAC Recombinant Influenza Vaccine Sales Market Share by Region in 2026

Figure 44. APAC Recombinant Influenza Vaccine Revenue Market Share by Region (2021-2026)

Figure 45. APAC Recombinant Influenza Vaccine Sales Market Share by Type (2021-2026)

Figure 46. APAC Recombinant Influenza Vaccine Sales Market Share by Application (2021-2026)

Figure 47. China Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 48. Japan Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 49. South Korea Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 50. Southeast Asia Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 51. India Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 52. Australia Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 53. China Taiwan Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 54. Europe Recombinant Influenza Vaccine Sales Market Share by Country in 2026

Figure 55. Europe Recombinant Influenza Vaccine Revenue Market Share by Country (2021-2026)

Figure 56. Europe Recombinant Influenza Vaccine Sales Market Share by Type (2021-2026)

Figure 57. Europe Recombinant Influenza Vaccine Sales Market Share by Application (2021-2026)

Figure 58. Germany Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 59. France Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 60. UK Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 61. Italy Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 62. Russia Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 63. Middle East & Africa Recombinant Influenza Vaccine Sales Market Share by Country (2021-2026)

Figure 64. Middle East & Africa Recombinant Influenza Vaccine Sales Market Share by Type (2021-2026)

Figure 65. Middle East & Africa Recombinant Influenza Vaccine Sales Market Share by Application (2021-2026)

Figure 66. Egypt Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 67. South Africa Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

millions)

Figure 68. Israel Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 69. Turkey Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 70. GCC Countries Recombinant Influenza Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 71. Manufacturing Cost Structure Analysis of Recombinant Influenza Vaccine in 2026

Figure 72. Manufacturing Process Analysis of Recombinant Influenza Vaccine

Figure 73. Industry Chain Structure of Recombinant Influenza Vaccine

Figure 74. Channels of Distribution

Figure 75. Global Recombinant Influenza Vaccine Sales Market Forecast by Region (2027-2032)

Figure 76. Global Recombinant Influenza Vaccine Revenue Market Share Forecast by Region (2027-2032)

Figure 77. Global Recombinant Influenza Vaccine Sales Market Share Forecast by Type (2027-2032)

Figure 78. Global Recombinant Influenza Vaccine Revenue Market Share Forecast by Type (2027-2032)

Figure 79. Global Recombinant Influenza Vaccine Sales Market Share Forecast by Application (2027-2032)

Figure 80. Global Recombinant Influenza Vaccine Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Recombinant Influenza Vaccine Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G91F888A87E2EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G91F888A87E2EN.html>